IPCA Laboratories share news, announcements and annual reports
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
IPCA Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Feb 1995 on NSE
Last close ₹1,927.80up ₹1.60 (0.08%)BSE ₹1,927.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,926.20.
30 Oct: open ₹1,945.20, high ₹1,964.90, low ₹1,921.40
52-week range of traded prices to 30 Oct 2026
₹1,268.00Low, 31 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹48,909 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.34
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,53,52767.6% delivered
IPCA Laboratories credit ratings
25 filed, newest first.
Jul 2026
7 Jul · Rating
Jul 2025
7 Jul · Rating
Jul 2024
16 Jul · Rating
Jul 2023
27 Jul · Rating
Oct 2022
14 Oct · Rating
Sep 2022
30 Sep · Rating
27 Sep · Rating
Oct 2021
29 Oct · Rating
Sep 2021
7 Sep · Rating
Aug 2021
30 Aug · Rating
Feb 2021
1 Feb · Rating
Sep 2020
2 Sep · Rating
Dec 2019
16 Dec · Rating
Aug 2019
30 Aug · Rating
Mar 2018
22 Mar · Rating
Jul 2017
5 Jul · Rating
Apr 2017
21 Apr · Rating
Jun 2016
Sep 2015
Sep 2013
Oct 2012
Jul 2011
Apr 2011
Apr 2008
24 Apr · Rating
Ipca Laboratories Ltd. has informed the Exchange that : "CRISIL has assigned its bank loan rating of AA-/ Stable to Company's bank facilities and re-affirmed its rating Pl+ on Company's short term debt programme."